Stocktoria
Acurx Pharmaceuticals, Inc. ACXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-25
Acurx Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $1.8M | $5.4M | $6.0M | $4.8M | $2.0M |
| SG&A expense | — | — | — | — | $208,270 |
| Operating income | -$8.1M | -$14.1M | — | — | — |
| Income tax | — | — | — | $0 | — |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| EPS (diluted) | $-5.32 | $-17.45 | $-1.15 | $-1.12 | $-1.49 |
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
| Shareholders' equity | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M |
Source: SEC EDGAR filings · CIK 0001736243 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.